GLP-1 for PCOS and Trying to Conceive: Timing the Off-Ramp

If you have PCOS, and trying to conceive is on your near-term horizon — within the next year, say, or even the next two — the GLP-1 conversation gets planned around your fertility window, not the other way around. If a licensed clinician determines GLP-1 therapy is appropriate for you, the medication, dosing, and monitoring decisions are theirs to make — what changes when TTC is on the horizon is the off-ramp.

This post is the off-ramp playbook. It covers the washout windows for semaglutide and tirzepatide, why those windows exist, what contraception you need during therapy (and the OCP-absorption caveat that PCOS patients should know about), how to bridge during the washout and into TTC, and what happens if pregnancy occurs accidentally on therapy. The goal is to make the timing decisions concrete enough that you and your clinician can lay out a calendar.

Why the washout exists

GLP-1 receptor agonists are not used during pregnancy or breastfeeding. That is the consistent position across the FDA labeling for the brand-name products, the 2023 International Evidence-Based PCOS Guideline, and the obstetric and endocrine societies that have weighed in.

The reason is exposure caution, not confirmed harm. Human pregnancy safety data on these medications is still limited because the studies that build that dataset have not yet been conducted at scale — and the studies that have been conducted (mostly small registry analyses and accidental-exposure case series) have not produced a clear signal of teratogenicity. But the absence of evidence of harm is not evidence of absence of harm, and animal studies have raised concerns: in some species, GLP-1 exposure during gestation has been associated with skeletal abnormalities and fetal growth reduction.

In the face of limited human data plus some animal-study concern, the regulatory and clinical consensus is to avoid the exposure. That means washing out before conception, not using the medication during pregnancy, and not using it during breastfeeding.

The washout windows

The washout window for each medication is set by the medication's half-life — the time it takes the body to clear approximately half of a given dose. The practical rule of thumb in pharmacology is that five half-lives clears about 97% of the medication, which is taken as the functional "drug is gone" mark. Regulatory washout guidance then adds a safety margin on top of that.

Semaglutide. Half-life approximately 7 days. Five half-lives = 35 days, roughly. Current labeling guidance is to discontinue semaglutide at least two months (about eight weeks) before a planned pregnancy. The eight-week recommendation incorporates the five-half-life mark plus a safety buffer.

Tirzepatide. Half-life approximately 5 days, so roughly 25 days for five half-lives. Unlike semaglutide, the tirzepatide labeling does not specify a pre-conception washout interval — the four-to-five-week figure often quoted is an extrapolation from that half-life, not a labeled instruction. Your prescriber sets the actual interval.

Liraglutide. Half-life approximately 13 hours. The washout is short — typically a few days — though if you are on liraglutide and planning pregnancy, the discussion happens with the clinician at the timing decision, not in advance.

For PCOS patients planning conception, the washout window is what makes the broader timeline work backward from a target conception date. If you are TTC in six months, you are on therapy for the next ~four months and washing out for the last two. If you are TTC in twelve months, you have a full eight or nine months on therapy before the washout starts. The clinician helps you plan that calendar.

Contraception during therapy

For any reproductive-age PCOS patient on GLP-1 therapy who is not actively trying to conceive, effective contraception is part of the protocol. That is true for all GLP-1 use — not specific to PCOS — but PCOS patients should be especially careful for two reasons.

First, PCOS itself is associated with cycle irregularity, and some patients with PCOS have experienced changes in cycle patterns during GLP-1 therapy in published reports; ovulation can return in a patient who was anovulatory for years. If ovulation returns — whatever the cause — accidental pregnancy becomes more likely than it was before. Contraception planning has to keep up.

Second, oral contraceptive pills are commonly used in PCOS for cycle and androgen management, and the interaction guidance here is drug-specific rather than a general GLP-1 rule.

Tirzepatide carries a labeled oral-contraceptive interaction: it delays gastric emptying enough to reduce absorption of oral hormonal contraceptives, and the labeling advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. That is a labeled instruction, not a conservative extra precaution.

Semaglutide labeling reports no clinically relevant effect on oral-contraceptive exposure.

If pregnancy would be unwelcome right now and you are relying on the pill, this is a conversation to have with your clinician before the first dose.

Non-oral contraceptive methods — IUD, implant, ring, patch — are not affected by GLP-1's gastric-emptying effect and can be a cleaner choice during therapy if cycle and androgen management are already addressed by other means.

Bridging from GLP-1 to TTC

The washout window between stopping the medication and starting to try to conceive is not a clinical no-man's-land. It is a window where your clinician will plan a bridge to preserve as much of the metabolic and cycle progress you have built as possible.

The most common bridging tools are metformin and myo-inositol. Both have been used in PCOS care for decades, both improve insulin sensitivity through different mechanisms than GLP-1, and both have well-characterized safety profiles in pregnancy and TTC. Metformin in particular has a large body of evidence supporting its use through TTC and even into early pregnancy in some clinical contexts (the call is made by the obstetric team based on individual factors). Myo-inositol, often paired with D-chiro-inositol, has been used routinely in PCOS pre-conception care.

Lifestyle intervention does the rest of the bridging work. In studies and clinical experience, weight and insulin-sensitivity changes achieved during GLP-1 therapy tend to decline gradually rather than reverse immediately after stopping, and cycle changes some patients experience may carry into the TTC window — though individual results vary and no outcome is guaranteed. Some clinicians suggest that the months following washout can be a reasonable window to begin trying to conceive, since the medication has cleared; your clinician and obstetric team will advise on timing for your situation.

The bridging plan looks different for different patients. A patient who lost 25 pounds on GLP-1 and is now near a healthy BMI might bridge with inositol and lifestyle alone. A patient with significant insulin resistance and a long history of failed lifestyle intervention will likely bridge with metformin (and possibly inositol). The plan is made individually, not from a template.

What happens if pregnancy is accidental

Despite contraception, accidental pregnancy on GLP-1 does happen — particularly in PCOS patients whose cycles have regularized on therapy. The protocol for this is:

1. Stop the medication immediately upon a confirmed positive test.
2. Tell your clinician right away. Tell the obstetric team that you were on GLP-1 at conception and through the early gestational period.
3. The obstetric team takes over the care plan. Most published case series of accidental GLP-1 exposure during conception and early pregnancy have not shown a clear pattern of harm, but the dataset is small and the obstetric team will monitor accordingly.

The honest framing here: accidental pregnancy on GLP-1 is not a confirmed catastrophe based on what we know, but it is a real exposure during a developmental window where we have limited safety data. The protocol exists because the right move is to remove the exposure and pivot care, not to panic.

What about breastfeeding

GLP-1 medications are not used during breastfeeding either. If you delivered while still in a planned pregnancy and want to restart GLP-1, the typical guidance is to wait until breastfeeding is complete. The reason is again the limited human safety data, this time on infant exposure through breast milk.

Some patients discuss restarting GLP-1 therapy with their clinician after delivery and breastfeeding as part of postpartum metabolic care. Whether that is appropriate — and what it may accomplish — is an individualized clinical decision.

How TelePeptide handles this

When a PCOS patient comes through intake and mentions TTC plans in the medical history, the clinician builds the protocol around the fertility timeline from day one. The medication choice (semaglutide vs. tirzepatide), the dose plan, the contraception conversation, the washout calendar, and the bridging plan are all part of the intake visit.

If TTC plans change mid-protocol — they often do, in either direction — the protocol gets revised at the next clinician check-in. The decision-making is shared, and the calendar is concrete enough to actually plan around.

We do not promise pregnancy or fertility outcomes. We do not advertise GLP-1 as a fertility medication. What we do is provide access to independent licensed clinicians who, when appropriate, may prescribe clinician-supervised compounded therapy as part of an individualized metabolic care plan — and we help plan the off-ramp carefully so that any medication is fully washed out before conception.

---

This article is for education, not medical advice. Compounded medications are not FDA-approved for any indication, and GLP-1 use for PCOS is off-label. A prescription is never guaranteed — an independent licensed clinician determines whether any treatment is appropriate — and individual results vary; no outcome is guaranteed. Pregnancy planning while on or after GLP-1 therapy is an individualized clinical decision. Discuss your specific timeline, history, and contraception with your prescribing clinician.

---

Editorial note: TelePeptide (the company) is a US direct-pay telehealth practice offering clinician-supervised compounded peptide therapy in 48 US states + DC. The brand name is sometimes autocorrected to "telopeptide" — an unrelated collagen biomarker; the two terms have no clinical connection.